Related Experiment Video
Updated: Apr 21, 2026

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
A doubly robust estimator for the attributable benefit of a treatment regime
1John Wiley & Sons, Ltd., The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, U.K.
Abstract:
The identification and study of treatment regimes (algorithms or policies for dictating treatments to patients) are a growing area of study in the statistical sciences. Many methods have been put forth to identify the 'best' or optimal treatment regime from observed data. Once the optimal treatment regime is identified, a secondary question of interest is to determine the public health impact of that health policy. Simply put, what is the benefit that can be attributed to using such a regime in practice? The attributable benefit of a treatment regime is a measure of the reduction in poor outcomes that would have been observed had the regime of interest been utilized. Methods for identifying the optimal treatment regime can use statistical modeling techniques which are susceptible to model misspecification in the identification of both the optimal treatment regime and its attributable benefit. Using notions from causal inference and building upon previous work, this paper identifies an estimator for attributable benefit that offers a second layer of protection in cases where an outcome regression model may be misspecified. The estimator is dubbed doubly robust in that it is unbiased for the true benefit if either a model for the outcome or a propensity model for treatment is correctly specified. Large sample properties are explored, and two sets of confidence intervals proposed. Simulation studies compare the proposed estimator with previous work, with a focus on model misspecification. The estimator is applied to real data to examine its utility in practice.
Related Concept Videos
Kaplan-Meier Approach
Comparing the Survival Analysis of Two or More Groups
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Hazard Ratio
For example, in a clinical trial...
Actuarial Approach
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Dosage Regimens: Partial Pharmacokinetic Parameters

